EP2155698A1 - Nouvelle forme polymorphe l de létrozole thermodynamiquement stable - Google Patents

Nouvelle forme polymorphe l de létrozole thermodynamiquement stable

Info

Publication number
EP2155698A1
EP2155698A1 EP07736572A EP07736572A EP2155698A1 EP 2155698 A1 EP2155698 A1 EP 2155698A1 EP 07736572 A EP07736572 A EP 07736572A EP 07736572 A EP07736572 A EP 07736572A EP 2155698 A1 EP2155698 A1 EP 2155698A1
Authority
EP
European Patent Office
Prior art keywords
letrozole
polymorphic form
preparation
gms
novel crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07736572A
Other languages
German (de)
English (en)
Inventor
Amala Kishan Kompella
Sreenivas Rachakonda
A. K. S. Rao
Nannapaneni Venkaiah Chowdary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natco Pharma Ltd
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of EP2155698A1 publication Critical patent/EP2155698A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • the present invention relates to a novel crystalline form L of letrozole and a process for preparing the same.
  • Letrozole is approved by the USFDA for the first-line treatment in post-menopausal women with hormone receptor positive (or) locally advanced (or) metastatic breast cancer.
  • a novel polymorph L of Letrozole is prepared by employing the following specific procedures.
  • polymorphic behavior of drugs can be of crucial importance in pharmacy and pharmacology.
  • Polymorphs are, by definition, crystals of the same molecule having different physical properties as a result of the order of changes in the molecules in the crystal lattice.
  • the differences in physical properties exhibited by polymorphs affect pharmaceutical parameters such as storage stability, compressibility and density (important in formulation and product manufacturing), and dissolution rates (an important factor in determining bio-availability).
  • Differences in stability can result from changes in chemical reactivity or mechanical changes or both. For example, a dosage form originating from one polymorph might discolor more rapidly when compound to another from a different polymorph. Or tablets might crumble on storage as a kinetically favoured polymorph spontaneously converts into a thermodynamically more stable polymorphic form.
  • some polymorphic transitions may result in lack of potency or, at the other extreme, toxicity.
  • the physical properties of the crystal may be important in processing: for example, one polymorph might be more likely to form solvates or might be difficult to filter and wash free of impurities
  • the most important solid state property of a pharmaceutical substance is its rate of dissolution in aqueous fluid.
  • the rate of dissolution of an active ingredient in a patients gastric fluid may have therapeutic consequences as it imposes an upper limit on the rate at which an orally-administered active ingredient reaches the blood stream.
  • the solid state polymorphic form of a compound may also affect its behavior on compaction and its storage stability.
  • the polymorphic form may give rise to thermal behavior different form that of the amorphous material (or) another polymorphic form.
  • Letrozole exists in a stable polymorphic form under certain experimental conditions of isolation or purification.
  • the main objective of the present invention is to provide a novel crystalline polymorphic form L of Letrozole
  • Another objective of the present invention is to provide processes for the preparation of novel crystalline polymorphic form L of Letrozole.
  • Yet another objective of the present invention is to provide processes for producing thermodynamically stable polymorphic form L of Letrozole. Description of the invention :
  • the present invention relates to a novel crystalline thermodynamically stable form L of Letrozole and processes for the preparation of the said form.
  • Form L is stable, and retains its crystalline structure and polymorphic identity after heating to 80 0 C for 10- 12 hrs.
  • stable refers to a polymorphic change of less than about 5% by weight, more preferably less than about 2%.
  • the present invention provides novel crystalline form L of Letrozole which is stable at room temperature and even at higher temperatures like 80 0 C having the XRD characteristics given in Table-I
  • PXRD patterns were recorded using a X-ray powder diffractometer (Bruker AXS D5000) in transmission mode (Cu K alpha I 5 PSD).
  • IR absorption spectra were measured in the spectral range 4000-400 cm "1 on a Bruker IFS48. Spectral resolution was 2 cm '1 . Sample preparation was performed generally as KBr disk.
  • the present invention provides a novel stable crystalline form L of letrozole and process for preparing the same.
  • Polymorph L of Letrozole of the present invention is prepared by
  • Solvent recrystallization methods where in the drug substance in its less pure form is crystallized from a select solvent.
  • the solvents for this purpose are selected from methanol, isopropanol, chloroform, Ethyl acetate, Dioxane and the like.
  • Lyophilization / freeze drying techniques where in the drug substance letrozole is dissolved in an alcoholic solvents like methanol and the clarified solution is subjected to lyophilization.
  • iii) Precipitation methods where in the drug substance letrozole in its less pure form is dissolved in solvents like Methano, DMF, acetic acid and the pure product is precipitated by addition of anti-solvents like water, isopropanol, isopropyl ether and the like, iv) Regeneration methods wherein the drug substance Letrozole in its less pure form is dissolved in an acid solution and the pure product is regenerated by addition of a base.
  • the acids used for this purpose are dil.hydrochloric acid, dilute sulfuric acid, dilute acetic acid and the like.
  • the bases employed for regeneration of the product are aqueous ammonia, dil. sodium hydroxide and the like.
  • Fig. IA of the drawings accompanying these specifications shows the X-Ray Powder Diffraction (XRPD) pattern which substantially depicts a typically pure sample of Letrozole of form L prepared by the process disclosed in the Example- 1 given below.
  • XRPD X-Ray Powder Diffraction
  • the infrared spectrum of form L as a KBr pellet has the characteristic absorptions at the following wavelengths (in cm "1 , f for weak, m for average, s for strong):
  • the present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of Form L of letrozole.
  • the dosage form of the formulation containing the novel, stable L form prepared by the process of the present invention may be a tablet containing the composition described in Example -17
  • the excipients which may be employed include micro crystalline cellulose, lactose, Sodium Starch Glycolate IP, colloidal silicondioxide magnesium stearate and talc
  • This invention also relates to a method for treating patients suffering from breast cancer by administering a therapeutically effective amount of the pharmaceutical composition of Form L of letrozole.
  • novel crystal form of the compound (I) according to the present invention is suitable in the same way as the compound (I) itself and thus making available for medicaments useful in the treatment of breast cancer.
  • Example-l The drug substance Letrozole was prepared by an adaptation of the procedure given in EP236940 (1987) as described below.
  • Letrozole crude (10 gms) obtained directly from the synthesis was dissolved in Methanol(200 ml) and heated to reflux during 30 minutes. The reaction mass was stirred at reflux temperature for 20 minutes and cooled to 0-5 0 C slowly during 1 hour. The reaction mass was filtered and washed with methanol. The wet product was dried under vacuum for 6 hours at 45-50 0 C. The yield was 8.9 gms of Letrozole form L. DSC Thermogram 186.3°C (Peak)
  • Letrozole crude (10 gms) obtained directly from the synthesis was dissolved in Ethyl formate(100 ml) and heated to reflux during 30 minutes .
  • the reaction mass was stirred at reflux temperature for 20 minutes and cooled to room temperature during 30 minutes.
  • the reaction mass was filtered and washed with Ethyl formate.
  • the wet product was dried under vacuum for 6 hours.
  • the yield was 7.8 gms of Letrozole form Z.
  • Letrozole crude (10 gms) obtained directly from the synthesis was dissolved in DMF (50 ml), demineralized water (500 ml) was added slowly during 15 minutes at the same temperature The reaction mass was stirred for 1 hour, filtered and washed with demineralized water. The wet product was dried under vacuum for 6 hours. The yield was 7 gms of Letrozole form L.
  • Letrozole crude (5 gms) obtained directly from the synthesis was dissolved in chloroform (100 ml) and THF (25 ml). The reaction mass was distilled under vacuum to a residual volume of 25 ml. The residual reaction mass was brought to 25-30 0 C and maintained at the same temperature for 20-30 minutes. Filtered ..washed with Acetone and dried to yield 2.9 gms of letrozole form L DSC Thermogram 184.7 0 C (Peak)
  • Letrozole crude (5 gms) obtained directly from the synthesis was dissolved in chloroform (100 ml) and isopropanol (25 ml). The reaction mass was distilled under vacuum to a residual volume of 50 ml. The residual reaction mass was brought to 25- 30 0 C and 85ml isopropanol was charged . The reaction mass was maintained at the same temperature for 20-30 minutes filtered and washed with isopropanol. The yield was 3.1 gms of letrozole form L DSC Thermogram 186.1°C (Peak)
  • Letrozole crude (1 gms) obtained directly from the synthesis was dissolved in DMF (10 ml). Isopropyl ether (40 ml) was added slowly during 15 minutes at the same temperature The reaction mass was stirred for 1 hour, filtered and washed with IPE. The wet product was dried at 50°C under vacuum for 6 hours. The yield was 0.3gms of Letrozole form L.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle forme cristalline L de létrozole, ainsi qu'un procédé permettant de préparer celle-ci. Le létrozole est utilisé pour le traitement de première intention chez les femmes post-ménopausées présentant un cancer du sein à récepteurs hormonaux positifs ou localement évolué ou métastatique.
EP07736572A 2007-01-22 2007-03-20 Nouvelle forme polymorphe l de létrozole thermodynamiquement stable Withdrawn EP2155698A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN148CH2007 2007-01-22
PCT/IN2007/000112 WO2008090565A1 (fr) 2007-01-22 2007-03-20 Nouvelle forme polymorphe l de létrozole thermodynamiquement stable

Publications (1)

Publication Number Publication Date
EP2155698A1 true EP2155698A1 (fr) 2010-02-24

Family

ID=38617241

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07736572A Withdrawn EP2155698A1 (fr) 2007-01-22 2007-03-20 Nouvelle forme polymorphe l de létrozole thermodynamiquement stable

Country Status (2)

Country Link
EP (1) EP2155698A1 (fr)
WO (1) WO2008090565A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608904A1 (fr) 2005-07-06 2007-09-07 Sicor Inc. Procede ameliore de fabrication de letrozole
CN102070541B (zh) * 2010-10-25 2013-07-10 深圳海王药业有限公司 来曲唑i型结晶及其制备方法
CN109721557A (zh) * 2017-10-27 2019-05-07 中国医学科学院药物研究所 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途
CN109721558A (zh) * 2017-10-27 2019-05-07 中国医学科学院药物研究所 来曲唑晶iii型固体物质及制备方法和其药物组合物与用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
EP1594850A2 (fr) * 2003-02-06 2005-11-16 Sun Pharmaceuticals Industries Ltd. Procede regiospecifique pour la preparation de 4- 1- (4-cyanophenyl)-1-(1,2,4-triazol-1-yl)methyl]benzonitrile
US20070100149A1 (en) * 2005-11-02 2007-05-03 Palle Venkata Raghavendra A Process for preparing letrozole
US7465749B2 (en) * 2005-11-14 2008-12-16 Chemagis, Ltd. Letrozole purification process

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008090565A1 *

Also Published As

Publication number Publication date
WO2008090565B1 (fr) 2008-11-06
WO2008090565A1 (fr) 2008-07-31

Similar Documents

Publication Publication Date Title
JP5159788B2 (ja) １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼン１／２水和物の結晶形
US10035802B2 (en) Solid state forms of ibrutinib
JP5535082B2 (ja) ボセンタン、その多形形態及びその塩の合成方法
CA2672549A1 (fr) Formes cristallines amorphes de losartan potassique et leur procede de preparation
EA025438B1 (ru) КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
WO2012068441A2 (fr) Sels d'intedanib et leurs formes à l'état solide
KR20160003899A (ko) 마크롤리드 고체상 형태
TWI518072B (zh) 塔適那偉（ａｔａｚａｎａｖｉｒ）硫酸氫鹽之製法及其新穎的形式
US20210292276A1 (en) Polymorphic forms of belinostat and processes for preparation thereof
WO2009146325A1 (fr) Formes polymorphes et amorphes de lacosamide et compositions amorphes
US8252805B2 (en) Forms of lapatinib ditosylate and processes for preparation thereof
WO2009064479A1 (fr) Formes polymorphes de l'hémifumarate d'aliskiren et procédé pour la préparation de celles-ci
US20210292479A1 (en) Solid state forms of sugammadex sodium
WO2021236709A1 (fr) Formes à l'état solide de tapinarof
US10351574B2 (en) Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
WO2008090565A1 (fr) Nouvelle forme polymorphe l de létrozole thermodynamiquement stable
JP2004520446A (ja) ロサルタンカリウムの結晶化方法
TWI399374B (zh) 新穎晶體形式及製備方法以及其醫藥組合物
KR101316653B1 (ko) 헤테로고리 화합물의 제조방법
WO2017167949A1 (fr) Formes cristallines de bilastine
US20200283381A1 (en) Solid state forms of elafibranor
KR20090044694A (ko) 모사프리드의 신규한 동질이상체 및 유사동질이상체
EP2072510A1 (fr) Forme cristalline d'azélastine
EP4229057A1 (fr) Formes à l'état solide de lorécivivint
WO2021046014A1 (fr) Formes à l'état solide de pamiparib et leurs procédés de préparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20100324

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130527